Psilocybin rescheduling petition gains urgency as attorney says Trump's psychedelics executive order should push DEA to act on a doctor's long-pending request

Psilocybin rescheduling has become more urgent as an attorney for the doctor behind a pending federal petition says President Trump's psychedelics executive order strengthens the case for DEA action. The core issue is whether the agency will reconsider psilocybin's Schedule I status in light of growing medical evidence and new federal interest in psychedelic treatment pathways. The petition centers on therapeutic use, especially for serious mental health conditions, and ties legal scheduling criteria to research showing clinical potential. Pressure on DEA comes from the mismatch between Schedule I restrictions and expanding recognition of psilocybin in medical and policy circles. Federal movement on rescheduling could affect research access, physician interest, and the future pace of regulated psychedelic medicine in the United States. A shift would also signal broader changes in how U.S. drug policy evaluates evidence, risk, and medical value for psychedelics.